Advanced search
Publication Cover
Reproductive Health Matters
An international journal on sexual and reproductive health and rights
Volume 22, 2014 - Issue sup44: Expanding access to medical abortion
Submit an article Journal homepage
4,473
Views
23
CrossRef citations to date
0
Altmetric
Original Research Articles

Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City

Patricio Sanhueza SmithCoordinator of Reproductive Health, Secretariat of Health of Mexico CityMexico CityMexico
,
Melanie PeñaDirector, Gynuity Health ProjectsNew YorkNYUSA
,
Ilana G DzubaSenior Program Associate, Gynuity Health ProjectsNew [email protected]
,
María Laura García MartinezDirector of Legal Abortion Program, Hospital Materno Infantil InguaránMexico CityMexico
,
Ana Gabriela Aranguré PerazaDirector of Reproductive Health Clinic, Centro de Salud Beatriz Velasco de AlemánMexico CityMexico
,
Manuel BousiéguezIndependent consultant, Mexico CityMexico
,
Tara ShochetProgram Associate, Gynuity Health ProjectsNew YorkNYUSA
&
Beverly WinikoffPresident, Gynuity Health ProjectsNew YorkNYUSA
 show all
Pages 75-82 | Published online: 18 Feb 2015

References

  • J Blum, S Raghavan, R Dabash. Comparison of misoprostol-only and combined mifepristone–misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. International Journal of Gynecology & Obstetrics. 118: 2012; 166–171. 10.1016/j.ijgo.2012.03.039.
  • B Winikoff, IG Dzuba, MD Creinin. Two distinct oral routes of misoprostol in mifepristone medical abortion: a randomized controlled trial. Obstetrics & Gynecology. 112: 2008; 1303–1310. 10.1097/AOG.0b013e31818d8eb4.
  • P Goldstone, J Michelson, E Williamson. Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study. Medical Journal of Australia. 197: 2012; 282–286.
  • S Raghavan, T Tsereteli, A Kamilov. Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: evidence from Uzbekistan. European Journal of Contraception and Reproductive Health Care. 18: 2013; 104–111. 10.3109/13625187.2013.763225.
  • H von Hertzen, NT Huong, G Piaggio, WHO Research Group on Postovulatory Methods of Fertility Regulation. Misoprostol dose and route after mifepristone for early medical abortion: a randomised controlled noninferiority trial. BJOG. 117: 2010; 1186–1196. 10.1111/j.1471-0528.2010.02636.x.
  • M Peña, IG Dzuba, P Sanhueza Smith. Efficacy and acceptability of a mifepristone–misoprostol combined regimen for early induced abortion among women in Mexico City. International Journal of Gynecology & Obstetrics. 127: 2014; 82–85. 10.1016/j.ijgo.2014.04.012.
  • World Health Organization. Safe Abortion: Technical and Policy Guidance for Health Systems. 2nd ed., 2012; WHO: Geneva. http://apps.who.int/iris/bitstream/10665/70914/1/9789241548434_eng.pdf.
  • D Becker, C Díaz Olavarrieta. Decriminalization of abortion in Mexico City: The effects on women’s reproductive rights. American Journal of Public Health. 103: 2013; 590–593.
  • Secretariat of Health of Mexico City. Information system of the Legal Termination of Pregnancy Program. Provisional data, June 2014.
  • M Mondragón y Kalb, A Ahued Ortega, J Morales Velazquez. Patient characteristics and service trends following abortion legalization in Mexico City, 2007–10. Studies in Family Planning. 42: 2011; 159–166.
  • B Winikoff, IG Dzuba, E Chong. Extending outpatient medical abortion services through 70 days of gestational age. Obstetrics & Gynecology. 120: 2012; 1070–1076. Doi: http://10.1097/AOG.0b013e31826c315f.
  • National Abortion Federation. 2014 Clinical Policy Guidelines. 2014; NAF: Washington, DC. http://prochoice.org/education-and-advocacy/2014-clinical-policy-guidelines/.
  • H Bracken, R Dabash, G Tsertsvadze. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days LMP: a prospective comparative open-label trial. Contraception. 89: 2014; 181–186. 10.1016/j.contraception.2013.10.018.
  • AA Boersma, B Meyboom-de Jong, G Kleiverda. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curaçao. European Journal of Contraception and Reproductive Health Care. 16: 2011; 61–66. 10.3109/13625187.2011.555568.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.